Of note, while ER positivity by IHC traditionally guides endocrine therapy selection in BC, it may not consistently correlate directly with activated ER signaling activity, which is a more accurate predictor of therapy responsiveness [120]. The gene discussed is ESR1; the disease is breast cancer.